Virulence factors of the Mycobacterium tuberculosis complex
MA Forrellad, LI Klepp, A Gioffré, J Sabio y Garcia… - Virulence, 2013 - Taylor & Francis
The Mycobacterium tuberculosis complex (MTBC) consists of closely related species that
cause tuberculosis in both humans and animals. This illness, still today, remains to be one of …
cause tuberculosis in both humans and animals. This illness, still today, remains to be one of …
Tuberculosis: what we don't know can, and does, hurt us
Mycobacterium tuberculosis has a penetrance of its host population that would be the envy
of most human pathogens. About one-third of the human population would have a positive …
of most human pathogens. About one-third of the human population would have a positive …
A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
S Bertholet, GC Ireton, DJ Ordway… - Science translational …, 2010 - science.org
Despite the widespread use of the childhood vaccine against tuberculosis (TB),
Mycobacterium bovis bacillus Calmette-Guérin (BCG), the disease remains a serious global …
Mycobacterium bovis bacillus Calmette-Guérin (BCG), the disease remains a serious global …
First-in-human trial of the post-exposure tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
AKK Luabeya, BMN Kagina, MD Tameris… - Vaccine, 2015 - Elsevier
Background H56: IC31 is a candidate tuberculosis vaccine comprising a fusion protein of
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
Ag85B, ESAT-6 and Rv2660c, formulated in IC31 adjuvant. This first-in-human, open label …
[HTML][HTML] Memory T Cells in Latent Mycobacterium tuberculosis Infection Are Directed against Three Antigenic Islands and Largely Contained in a CXCR3+CCR6+ …
An understanding of the immunological footprint of Mycobacterium tuberculosis (MTB) CD4
T cell recognition is still incomplete. Here we report that human Th1 cells specific for MTB …
T cell recognition is still incomplete. Here we report that human Th1 cells specific for MTB …
[HTML][HTML] Next-generation vaccines based on Bacille Calmette–Guérin
NE Nieuwenhuizen, SHE Kaufmann - Frontiers in immunology, 2018 - frontiersin.org
Tuberculosis (TB), caused by the intracellular bacterium Mycobacterium tuberculosis (Mtb),
remains a major health threat. A live, attenuated mycobacterium known as Bacille Calmette …
remains a major health threat. A live, attenuated mycobacterium known as Bacille Calmette …
Tuberculosis vaccines in clinical trials
R Rowland, H McShane - Expert review of vaccines, 2011 - Taylor & Francis
Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the
global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette …
global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette …
A review of the BCG vaccine and other approaches toward tuberculosis eradication
T Cho, C Khatchadourian, H Nguyen… - Human vaccines & …, 2021 - Taylor & Francis
Despite aggressive eradication efforts, Tuberculosis (TB) remains a global health burden,
one that disproportionally affects poorer, less developed nations. The only vaccine approved …
one that disproportionally affects poorer, less developed nations. The only vaccine approved …
Drugs in development for tuberculosis
AM Ginsberg - Drugs, 2010 - Springer
Tuberculosis (TB) drug research and development efforts have resurged in the past 10 years
to meet urgent medical needs, but enormous challenges remain. These urgent needs are …
to meet urgent medical needs, but enormous challenges remain. These urgent needs are …
[HTML][HTML] The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity
R Billeskov, TT Elvang, PL Andersen, J Dietrich - PloS one, 2012 - journals.plos.org
Background The current vaccine against tuberculosis (TB), BCG, has failed to control TB
worldwide and the protective efficacy is moreover limited to 10–15 years. A vaccine that …
worldwide and the protective efficacy is moreover limited to 10–15 years. A vaccine that …